Export

You can select particular sections to be included in the output file.

Model List of Essential Medicines

clear Found 41 recommendations for 33 medicines and 8 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
18. Medicines for endocrine disorders
  1. Alfacalcidol General information
    Section
    Medicines for endocrine disorders
    • Oral > Liquid: 2 µg per mL
    • Oral > Solid > capsule: 0.25 µg; 1 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  2. Bromocriptine General information
    Section
    Medicines for disorders of the pituitary hormone system
    Indications
    Therapeutic equivalent to cabergoline for Other specified benign neoplasm of endocrine glands
  3. Cabergoline General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Oral > Solid > tablet: 0.5 mg; 1 mg
    Indications
    Other specified benign neoplasm of endocrine glands
  4. Calcitriol General information
    Section
    Medicines for endocrine disorders
    • Oral > Solid > capsule: 0.25 µg; 0.5 µg
    Indications
    Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport
  5. Canagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  6. Carbimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole for Thyrotoxicosis
  7. Dapagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  8. Diazoxide General information
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
    Indications
    Persistent hyperinsulinaemic hypoglycaemia of infancy
  9. Empagliflozin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 10 mg; 25 mg
    Indications
    Type 2 diabetes mellitus
  10. Estradiol General information
    Section
    Estrogens
    • Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg
    Indications
    Gonadotropin deficiency Hypopituitarism Turner syndrome
  11. Fludrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 100 µg (acetate)
    Indications
    Adrenocortical insufficiency
  12. Glibenclamide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 5 mg; 2.5 mg
    Indications
    Type 2 diabetes mellitus
  13. Gliclazide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
    Indications
    Type 2 diabetes mellitus
  14. Glucagon General information
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL
    Indications
    Hypoglycaemia in the context of diabetes
  15. Hydrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
    Adrenocortical insufficiency
  16. Insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen (soluble)
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble); 100 IU per mL in 3 mL cartridge (soluble); 100 IU per mL in 3 mL pre-filled pen
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  17. Insulin analogues General information
    Section
    Insulins
    • Not specified
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  18. Insulin degludec General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus
  19. Insulin detemir General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin glargine for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus
  20. Insulin glargine General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
    Indications
    Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 1 diabetes mellitus Therapeutic equivalent to long-acting insulin analogues for Type 2 diabetes mellitus
  21. Intermediate-acting insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  22. Ketoconazole General information
    Section
    Medicines for endocrine disorders
    • Oral > Solid > tablet: 200 mg
    Indications
    Cushing syndrome
  23. Levothyroxine General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
    Hypothyroidism
  24. Liraglutide General information
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen
    Indications
    Obesity
  25. Long-acting insulin analogues General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
    Indications
    Type 1 diabetes mellitus Type 2 diabetes mellitus
  26. Lugol's solution General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
    Indications
    Thyrotoxicosis
  27. Medroxyprogesterone acetate General information
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle
  28. Metformin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
    Indications
    Type 2 diabetes mellitus
  29. Methimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
    Thyrotoxicosis
  30. Norethisterone General information
    Section
    Progestogens
    • Oral > Solid: 5 mg
    Indications
    Excessive menstruation with irregular cycle Therapeutic equivalent to medroxyprogesterone acetate for Excessive menstruation with irregular cycle
  31. Octreotide General information
    Section
    Medicines for disorders of the pituitary hormone system
    • Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
    • Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)
    Indications
    Acromegaly or pituitary gigantism
  32. Phosphorus General information
    Section
    Medicines for endocrine disorders
    • Oral > Other: 500 mg in sachet (elemental phosphorus) granules
    • Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)
    Indications
    Hypophosphataemic rickets
  33. Potassium iodide General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 60 mg
    Indications
    Thyrotoxicosis
  34. Propylthiouracil General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 mg
    Indications
    Thyrotoxicosis
  35. Simvastatin General information
    Section
    Medicines for endocrine disorders
    • Oral > Solid: 20 mg
    Indications
    Polycystic ovary syndrome
  36. Somatropin General information
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge
    Indications
    Hypoglycaemia without associated diabetes
  37. Testosterone General information
    Section
    Androgens
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)
    Indications
    Testicular dysfunction or testosterone-related disorders
  38. Tolbutamide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg
    Indications
    Type 2 diabetes mellitus
  39. Zoledronic acid General information
    Section
    Medicines for endocrine disorders
    • Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle
    Indications
    Osteogenesis imperfecta